… We argue here that genomic guidance should be embedded in all drug development and
treatment … used medications in clinical practice. The success of pharmacogenomics in GWAS …

… impact on the clinical practice of medicine. Herein, we discuss the potential implications
of pharmacogenomics on the drug development process, including drug safety, productivity, …

… development and clinical practice. SNP arrays covering 5 million SNPs will soon become
a reality, and the cost for whole-genome sequencing is rapidly decreasing, with companies …

… been incorporated into medical practise, despite the … use of pharmacogenomic testing
during drug development. The graph in Figure 1 shows the increase in pharmacogenomic clinical …

… drug development using pharmacogenomics as a tool and the diagnostic procedures all need
to be critically analysed. Pharmacogenomics … It is concerned with genetic effects on drugs …

… We propose a framework for the role of PGx in early-phase drug development and … principles
in clinical practice has been slow [4,32,37,45–48]. PGx-driven clinical practice guidelines …

… The advances and challenges in genetic-guided drug discovery and development,
pharmacogenetics and use of pharmacogenetics to guide treatment are discussed herein. …

… Meanwhile, technological efforts should be focused on the development of pharmacogenomic
bed tests which will definitively install pharmacogenomics into routine medical practice. …

… will be pharmacogenomics. This review discusses the pharmacogenomics of specific drug
… utility was based upon the frequency of pharmacogenomic testing in the clinical setting. For …

… pharmacogenomic information will have a large impact on drug development and,
subsequently, clinical practice… the routine use of pharmacogenomic testing in clinical practice. A …